Javascript must be enabled to continue!
Abstract 6093: Evaluation of preanalytical and physiological variables affecting cfDNA-based multi-cancer early detection test
View through CrossRef
Abstract
Background: The multi-cancer early detection (MCED) tests utilizing blood-based circulating cell-free DNA (cfDNA) have gained significant attention in the market as a promising approach for early cancer detection. However, potential effects of preanalytical and physiological variables, including extraction methods, preservation techniques, and physiological factors such as diet, on the accuracy and reliability of MCED results remains poorly investigated. In this study, we aimed to evaluate the impact of physiological variables during blood collection and preanalytical procedures on the outcomes of a MCED test.
Methods: A total of 105 plasma samples from 19 healthy donors was collected and analyzed using a MCED test (MERCURY) which leverages the low-coverage whole-genome sequencing and a set of genome-wide features based on cfDNA fragmentomics. Samples were controlled for preanalytical procedures, including transportation condition and preservation time or physiological conditions (before/after meal or exercise) at blood collection.
Results: Repeat blood collection (N=4) from the 5 healthy participants consistently yielded negative results for cancer (PPA: 100.0%; 95% CI [56.6%,100.0%]). Among the 5 healthy participants, plasma samples frozen within 1 year (7 days, 3 months, 9 months) showed the same agreement with the reference condition as non-frozen samples (PPA: 100.0%; 95% CI [56.6%,100.0%]), except for one sample frozen for 1 year, which showed a higher risk score and became a positive signal (PPA:80.0%; 95% CI [37.6%,96.4%]). Transportation conditions within 2 hours, 24 hours, 48 hours, and 96 hours at room temperature or 4℃ did not affect the test outcomes, as all samples remained in agreement with the reference condition as of 2 hours at 4℃ (PPA:100.0%; 95% CI [61.0%,100.0%]). Physiological conditions, including pre- and post-meal as well as pre- and post-exercise states, did not exert any influence on the test results, as all samples exhibited agreement with the reference condition (PPA:100.0%; 95% CI [43.9%,100.0%]).
Conclusions: The results of this study suggest that variables such as time of blood collection and plasma freezing time may not significantly affect the accuracy of the MCED test in healthy participants. Transportation conditions and physiological conditions evaluated in this study did not have a notable influence on the test outcomes. Nevertheless, it is advised that the freezing duration of plasma samples should not exceed one year.
Citation Format: Hua Bao, Xiaoxi Chen, Xuxiaochen Wu, Wanxiangfu Tang, Min Wu, Shiting Tang, Xue Wu, Yang Shao. Evaluation of preanalytical and physiological variables affecting cfDNA-based multi-cancer early detection test [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6093.
American Association for Cancer Research (AACR)
Title: Abstract 6093: Evaluation of preanalytical and physiological variables affecting cfDNA-based multi-cancer early detection test
Description:
Abstract
Background: The multi-cancer early detection (MCED) tests utilizing blood-based circulating cell-free DNA (cfDNA) have gained significant attention in the market as a promising approach for early cancer detection.
However, potential effects of preanalytical and physiological variables, including extraction methods, preservation techniques, and physiological factors such as diet, on the accuracy and reliability of MCED results remains poorly investigated.
In this study, we aimed to evaluate the impact of physiological variables during blood collection and preanalytical procedures on the outcomes of a MCED test.
Methods: A total of 105 plasma samples from 19 healthy donors was collected and analyzed using a MCED test (MERCURY) which leverages the low-coverage whole-genome sequencing and a set of genome-wide features based on cfDNA fragmentomics.
Samples were controlled for preanalytical procedures, including transportation condition and preservation time or physiological conditions (before/after meal or exercise) at blood collection.
Results: Repeat blood collection (N=4) from the 5 healthy participants consistently yielded negative results for cancer (PPA: 100.
0%; 95% CI [56.
6%,100.
0%]).
Among the 5 healthy participants, plasma samples frozen within 1 year (7 days, 3 months, 9 months) showed the same agreement with the reference condition as non-frozen samples (PPA: 100.
0%; 95% CI [56.
6%,100.
0%]), except for one sample frozen for 1 year, which showed a higher risk score and became a positive signal (PPA:80.
0%; 95% CI [37.
6%,96.
4%]).
Transportation conditions within 2 hours, 24 hours, 48 hours, and 96 hours at room temperature or 4℃ did not affect the test outcomes, as all samples remained in agreement with the reference condition as of 2 hours at 4℃ (PPA:100.
0%; 95% CI [61.
0%,100.
0%]).
Physiological conditions, including pre- and post-meal as well as pre- and post-exercise states, did not exert any influence on the test results, as all samples exhibited agreement with the reference condition (PPA:100.
0%; 95% CI [43.
9%,100.
0%]).
Conclusions: The results of this study suggest that variables such as time of blood collection and plasma freezing time may not significantly affect the accuracy of the MCED test in healthy participants.
Transportation conditions and physiological conditions evaluated in this study did not have a notable influence on the test outcomes.
Nevertheless, it is advised that the freezing duration of plasma samples should not exceed one year.
Citation Format: Hua Bao, Xiaoxi Chen, Xuxiaochen Wu, Wanxiangfu Tang, Min Wu, Shiting Tang, Xue Wu, Yang Shao.
Evaluation of preanalytical and physiological variables affecting cfDNA-based multi-cancer early detection test [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6093.
Related Results
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract
Backgroud: Tumor-derived circulating cell-free DNA (cfDNA) is a dynamic source for determination of tumor mutation status. We have previously demonstrated t...
Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract
Introduction: Detection of circulating free DNA (cfDNA) is a promising tool to monitor and predict tumor progression and treatment efficacy. Our group has s...
Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types.
Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types.
e13072 Background: Tumor cells keep shedding DNA into blood stream. Here we present a retrospective study to investigate the potential of CIN in plasma cell-free DNA (cfDNA) as a ...
Monitoring Circulating Cell-free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment - A Pilot Study
Monitoring Circulating Cell-free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment - A Pilot Study
Abstract
Purpose
Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularl...
Monitoring Circulating Cell-Free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment – A Pilot Study
Monitoring Circulating Cell-Free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment – A Pilot Study
PURPOSE: Monitoring circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervical ...
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Abstract
Purpose
Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularl...
Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery
Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery
Abstract
Surgical intervention is one of the most employed treatments for colorectal cancer, especially in patients with localized disease. However, the dynamics of ...
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
PURPOSE: Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervic...

